Cue Biopharma
CUE
29 hedge funds and large institutions have $25.9M invested in Cue Biopharma in 2018 Q1 according to their latest regulatory filings, with 29 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.32% more ownership
Funds ownership: 0% → 0.32% (+0.32%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
+$7.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.87M |
| 3 |
BlackRock
New York
|
+$6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.79M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.14M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $9K | +$10K | +22 | New |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $6K | +$6.38K | +14 | New |
|
28
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2K | +$1.37K | +3 | New |
|
|
LTFS
29
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | +$1.82K | +4 | New |
|
CUE Hedge Fund Activity: Q1 2018 in Review
29 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2018, worth a combined $25.9M.
Buyers outnumbered sellers: 29 funds opened new CUE positions and 0 closed out — a net gain of 29 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was First Eagle Investment Management, opening a new position worth an estimated $7.6M.
- 29 institutional investors held Cue Biopharma (CUE) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $25.9M of Cue Biopharma stock for Q1 2018.
- 29 funds opened new Cue Biopharma positions in Q1 2018 and 0 closed out, a net change of +29 holders.
- The largest Cue Biopharma buyer in Q1 2018 was First Eagle Investment Management, an estimated $7.6M added.
Based on aggregated 13F filings for Q1 2018.